Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Sulfuric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | BLM | P54132 | 2/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | CA5A | P35218 | 1/20 | 0.30 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sulfuric Acid SCHEMBL27636434 | 1.00 | KDM4E (0.44) | KDM4EBLMCYP2D6CYP2C19NPSR1 | |
| Sulfuric Acid SCHEMBL5837457 | 0.89 | KDM4E (0.34) | KDM4EBLMCYP2D6CYP2C19NPSR1 | |
| SCHEMBL27636433 | 0.89 | KDM4E (0.34) | KDM4EBLMCYP2D6CYP2C19NPSR1 | |
| SCHEMBL538974 | 0.87 | — | — | |
| Hydrochloric Acid SCHEMBL5837690 | 0.84 | — | — | |
| Acetic Acid SCHEMBL31317491 | 0.80 | TSHR (0.48) | BLMCYP2C19ALDH1A1TSHR | |
| Sulfuric Acid SCHEMBL601039 | 0.73 | KDM4E (0.52) | KDM4EBLMCYP2D6CYP2C19NPSR1 | |
| Sulfuric Acid SCHEMBL275165 | 0.73 | KDM4E (0.52) | KDM4EBLMCYP2D6CYP2C19NPSR1 | |
| Sulfuric Acid SCHEMBL28052558 | 0.73 | KDM4E (0.52) | KDM4EBLMCYP2D6CYP2C19NPSR1 | |
| Sulfuric Acid SCHEMBL2830996 | 0.73 | KDM4E (0.52) | KDM4EBLMCYP2D6CYP2C19NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119462497-A | Pyridopyrimidinone Process for the preparation of compounds | 上海皓元医药股份有限公司 | 2025-02-18 | — | — | CN | claimed |
| US-7105694-B2 | Reaction of cyanamide with isopropanol and sodium hydroxide and sulfuric acid | NIPPON CARBIDE KOGYO KABUSHIKI KAISHA (JP) | 2006-09-12 | — | — | US | claimed |
| US-20050171372-A1 | Novel o-isopropylisourea salts and process for the production thereof | NIPPON CARBIDE KOGYO KABUSHIKI KAISHA (JP) | 2005-08-04 | — | — | US | claimed |
| EP-1486484-A1 | NOVEL O-ISOPROPYLISOUREA SALTS AND PROCESS FOR THE PRODUCTION THEREOF | Nippon Carbide Kogyo Kabushiki Kaisha (JP) | 2004-12-15 | — | — | EP | claimed |
| CN-119462497-A | Pyridopyrimidinone Process for the preparation of compounds | 上海皓元医药股份有限公司 | 2025-02-18 | — | — | CN | disclosed |
| US-7105694-B2 | Reaction of cyanamide with isopropanol and sodium hydroxide and sulfuric acid | NIPPON CARBIDE KOGYO KABUSHIKI KAISHA (JP) | 2006-09-12 | — | — | US | disclosed |
| US-7105694-B2 | Reaction of cyanamide with isopropanol and sodium hydroxide and sulfuric acid | NIPPON CARBIDE KOGYO KABUSHIKI KAISHA (JP) | 2006-09-12 | — | — | US | disclosed |
| CN-1697827-A | Novel O-isopropyl isourea salt and process for producing the same | NIPPON CARBIDE KOGYO KK (JP) | 2005-11-16 | — | — | CN | disclosed |
| EP-1486484-A4 | NOVEL O-ISOPROPYLISOUREA SALTS AND PROCESS FOR THE PRODUCTION THEREOF | NIPPON CARBIDE KOGYO KK (JP) | 2005-11-02 | — | — | EP | disclosed |
| US-20050171372-A1 | Novel o-isopropylisourea salts and process for the production thereof | NIPPON CARBIDE KOGYO KABUSHIKI KAISHA (JP) | 2005-08-04 | — | — | US | disclosed |
| US-20050171372-A1 | Novel o-isopropylisourea salts and process for the production thereof | NIPPON CARBIDE KOGYO KABUSHIKI KAISHA (JP) | 2005-08-04 | — | — | US | disclosed |
| EP-1486484-A1 | NOVEL O-ISOPROPYLISOUREA SALTS AND PROCESS FOR THE PRODUCTION THEREOF | Nippon Carbide Kogyo Kabushiki Kaisha (JP) | 2004-12-15 | — | — | EP | disclosed |
| EP-1486484-A1 | NOVEL O-ISOPROPYLISOUREA SALTS AND PROCESS FOR THE PRODUCTION THEREOF | Nippon Carbide Kogyo Kabushiki Kaisha (JP) | 2004-12-15 | — | — | EP | disclosed |
| WO-2004067500-A1 | NOVEL O-ISOPROPYLISOUREA SALTS AND PROCESS FOR THE PRODUCTION THEREOF | NIPPON CARBIDE KOGYO KABUSHIKI KAISHA (JP) | 2004-08-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050171372-A1 | Novel o-isopropylisourea salts and process for the production thereof | MPST, TST, ADH1A | KDM4E 3951/4885BLM 4205/4885CYP2D6 2055/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.